Education/Professional Experience
1.1984.9 -1989.8: Jinzhou medical university, bachelor degree
2.1998.9 -2001.8：Dalian medical university, digestive system, master degree
3.2002.9 -2005.8：Shanghai TCM university, liver disease institute, integrate of TCM and western medicine, Ph.D.
4.1989.8-2002.8：Dalian 6th people’s hospital, liver disease department, vice professor, director.
5.2005.8-up to now：The first hospital of Dalian medical university, department of integrate of TCM and western medicine in liver disease
6.2013.11-2014.1: UPMC of American and Mayo clinic of American
Participation in the Academic Community
1.The first board of directors of the General Hospital of traditional Chinese medicine in the World Federation of Chinese Medicine Societies(2016.8-2020.8)
2.Member of the Third Committee of the infection control branch of the Chinese Preventive Medicine Association
3.Member of the hospital infection epidemic and outbreak group of the infection control branch of the Chinese Preventive Medicine Association
4.Young member of hospital infection management specialized committee of China Hospital Association
5.Member of the Integrated Traditional and Western Medicine on Liver Disease branch of Chinese Medical Doctor Association
6.Executive director of infectious disease branch of China Medical Association of Minorities
7.Executive director of the first academic committee of China Medical Bio-Immunological Institute
8.Deputy director of the third hospital infection management specialized committee of Preventive Medicine Association in Liaoning Province
9.Executive director of Second Committee of Liaoning Society of Hepatology
10.Executive Committee of the Infectious Diseases Society of Liaoning society of Integrated Traditional and Western Medicine
11.Member of the digestive internal medicine specialized committee of Liaoning society for cell biology
12.Vice chairman of Liver disease specialized committee of Liaoning society of Integrated Traditional and Western Medicine (2016.6-2010.7)
13.Vice chairman of the eleventh committee of infectious diseases and parasitic diseases of Liaoning Provincial Medical Association(Term of office 4 years, 2016.6-2020.6)
14.The chairman designate of the hospital infection control branch of Dalian Medical Association
15.Deputy director of infectious diseases branch of Dalian Medical Association
Member of Dalian society of Integrated Traditional and Western Medicine
16.Director of Liver disease branch of Dalian society of Integrated Traditional and Western Medicine
Publication
1·Zhang ZF,Yang N, Zhao G, Zhu L, Zhu Y, Wang LX. Preventive effect of ulinastatin and gabexate mesylate on post-endoscopic retrograde cholangiopancreatography pancreatitis. Chin Med J (Engl), 2010, 123(18): 2600-2606. (Corresponding author: ZhaoGang）
2·Zhang ZF, Yang N, Zhao G, Zhu L, Zhu Y, Wang LX. Effect of Helicobacter pylori radication on iron deficiency. Chin Med J (Engl), 2010, 123(14): 1924-1930. (Corresponding author:ZhaoGang)
3·Ying Zhu, Qing-Wei Cong, Yue Liu, Chun-ling Wan, Tao Yu, Guang He, Lin He, Lei Cai, Kuo-Chen Chou. Antithrombin, an Important Inhibitor in Blood Clots. Current Topics in Medicinal Chemistry. 2016; 16(6): 666-674.(IF 3.402,Corresponding author:Zhu Ying）
4·Xie QL, Zhu Y, Wu LH, Fu LL, Xiang Y.The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis. PloS One. 2015; 10(7):e0132219. (IF 3.234,Corresponding author:Zhu Ying）
5·Linghong Wu, Ying Zhu.The function and mechanisms of action of LOXL2 in cancer (Review).International Journal of Molecular Medicine. 2015;36: 1200-1204. (IF 2.088,Corresponding author:Zhu Ying）
6·Ling-Hong Wu, Yuan Zhang,Ying Zhu, Qing-Wei Cong, Lin-Lin Fu, Yan Xiang.Mechanism Analyses for Elucidating the Role of LOXL2-silencing in Hepatocellular Carcinoma. Journal of Agricultural Science and Technology A, 2015, 5: 370-379 (IF 0.699,Corresponding author:Zhu Ying）
7·Linlin Fu, Bingyao Pang, Ying Zhu, Ling Wang, Aijing Leng, Hailong Chen,Ex VivoStromal Cell-Derived Factor 1-Mediated Differentiation of Mouse Bone Marrow Mesenchymal Stem Cells into Hepatocytes Is Enhanced by Chinese Medicine Yiguanjian Drug-Containing Serum,Evidence-Based Complementary and Alternative Medicine,2016. (IF 1.88,Corresponding author:Zhu Ying）
8·Qiao-Ling Xie,Yue Liu, Ying Zhu, CRM1 expression and its relationship with clinical pathological features in primary carcinoma of the liver. Experimental and Therapeutic Medicine, 2016;12: 59-68. (IF 1.269,Corresponding author:Zhu Ying）
9·Linghong Wu, Yuan Zhang,Ying Zhu, Qingwei Cong, Linlin Fu, Yan Xiang. The basic and clinical research of LOXL2 in hepatocellular carcinoma. Molecular Medicine Reports. Accepted on September 6 ,2015.(IF 1.554,Corresponding author:Zhu Ying）
10·Yan Xiang, Yuan Zhang, Qiao-ling Xie, Ying Zhu, Ai-jing Leng, Long-qing Lu, Hai-long Chen. Effect of Yiguan Decoction on differentiation of bone Mesenchymal Stem Cells into Hepatocyte-like Cells in Demethylnitrosamine-induced Mice Liver Cirrhosis: an experimental Research. Molecular Medicine Reports. Accepted onDecember16,2015. (IF 1.554,Corresponding author:Zhu Ying）
11·Linlin Fu, Linghong Wu, Bingyao Pang, Ying Zhu, Ling Wang, Aijing Leng, Hailong Chen.Research of Yi Guan Jian decoction on enhancing hepatic differentiation of bone marrow-derived mesenchymal stem cells via SDF-1 in vitro. Molecular Medicine Reports. Accepted on January 15, 2016.
Research Projects/Grants
1·Responsible for the projectthat“Multi drug resistant mechanism and molecular epidemiology of beta-lactamases producing Klebsiella pneumoniae by hospital infection inDalian area”in 2009（2009E12SF153）Set up the projectin Dalian Municipal Science and Technology Bureau
2·Project in 2009“Clinical application and technology platform of Chinese and English stem cells”（item number：2009F11GH178） Project leader of liver stem cell treatment group . Stand as international cooperation project of Dalian Municipal Science and Technology Bureau.300 thousand
3·Medical peak construction project in Liaoning Province “Peripheral blood stem cell transplantation in the treatment of chronic liver disease”, number: 200919, sources of funds:Health Department of Liaoning Province, Starting and ending time: January 1, 2010 - December 31, 2012 ,I am responsible for viral liver disease stem cell transplantation research,funds: 200 thousand.
4·Responsible for the projectthat“Effect of a H1N1 influenza virus antigen on the expression of CD4+-CD25+-Foxp3 regulatory T cells”in 2010（L2010128）Set up the project in the Provincial Department of Education , 30 thousand
5·Responsible for the projectthat“Study on the regulation mechanism of Wnt signaling pathway in BMSCs hepatic differentiation inYiguan Jian Decoction”in 2012,（2012E15SF143) Set up the project inDalian Municipal Science and Technology Bureau.
6·Responsible for the projectthat“The mechanism of Yiguan Jianregulating SDF-1/CXCR4 signaling pathway inpromoting marrow stem cell migration and differentiation in the treatment of liver cirrhosis”in 2012,（81273925）Set up the project in National Natural Science Foundation of China, funds: 710 thousand yuan.
7·Responsible for the projectthat“Clinical study on the treatment of chronic hepatitis B patients with emtricitabine after the market”in 2014（W2014HB038）, Science and technology development center of the State Health Planning Commission, January 2015 -2017 June.
8·Responsible for the projectthat“Study on HBx promoting proliferation of hepatocellular carcinoma cell line pass through LOXL2 mediated signaling pathway”in 2015（2015020305）, Set up the project in Liaoning province science and Technology Department, funds: 50 thousand yuan, 2015.7-2018.6.
9·Responsible for the projectthat “Study on the mechanism of inhibiting liver cancer stem cells to treat liver cancer by Yiguan Jian through the LOXL2 pathway”in 2016, Set up the project in National Natural Science Foundation of China, funds: 690 thousand yuan.2017.1-2020.12.
AdmissionPlan/Requirements
1.Master graduate(1person):
Integrate of TCM and western medicine in liver disease. CET6.
2.Doctoral candidate(1 person): (1) Digestive system in liver disease. (2) Integrate of TCM and western medicine in liver disease. CET6.
